Roberto Gedaly, MD
Transplant Surgery · Lexington, KYNPI 1962469361
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Merck accounts for 70.8% of it on its own, with 1 other manufacturer making up the rest. 2025 is the largest year on record at $96, 5.5 times the $17 reported in 2019.
Across 3 payments — averaging $44.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$96
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$39
Across 31 payments — averaging $18,301 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$338K
- Veloxis Pharmaceuticals, Inc.$139K
- Shire North American Group Inc$56K
- Takeda Pharmaceuticals U.S.A., Inc.$24K
- Modernatx, Inc.$10K
What the payments were for
- Food & beverage$135100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 1 | $96 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $39 |
How this compares
Too few transplant surgery providers in Kentuckyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Valganciclovir Hcl | 15 | $4,320 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 16 | $889 |
| Nifedipine ErNifedipine | 17 | $261 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 52 | $258 |
| Prednisone | 17 | $107 |
| Famotidine | 16 | $75 |
Paid to pharmacies, not to this prescriber.
Other transplant surgery in Lexington
- Alejandro Cracco MahechaLexington$5K
- Malay ShahLexington$5K
- Meera GuptaLexington$3K
- Siddharth DesaiLexington$3K
- Alexandre AnchetaLexington$3K
- Matthew BlackLexington$2K
- Erin MaynardLexington$536
- Eric DavisLouisville$78K
- Christopher JonesLouisville$34K
- Mary EngLouisville$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.